| OPPOSITION | - Anonymous, "Global strategy for the diagnosis management, and prevention of chronic obstructive pulmonary disease", Global Initiative for Chronic Obstructive Disease, (20130101), pages 1 - 99, XP055736139 |
| OPPOSITION | - Anonymous, "Relvar Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed", EMC - Summary of Product Characteristics (SmPC), (20220330), pages 1 - 13, EMC - Summary of Product Characteristics (SmPC) , URL: https://www.medicines.org.uk/emc/product/5225/smpc/print, XP093192240 |
| OPPOSITION | - Anthonisen Nicholas R., John E. Connett, James P. Kiley, Murray D. Altose, William C. Bailey, A. Sonia Buist, William A. Conway, Paul L. Enright, Richard E. Kanner, Peggy O’hara, Gregory R. Owens, Paul D. Scanlon, Donald P. Tashkin, Robert A. Wise,, "Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEVlThe Lung Health Study", JAMA The Journal ofthe American Medical Association, (19941101), vol. 272, no. 9, pages 1497 - 1505, XP093192218 |
| OPPOSITION | - Brunton Laurence L., "NOVEL CLASSES OF BRONCHODILATORS", Goodman and Gilman's The Pharmacological Basis of Therapeutics, Twelfth Edition, McGraw-Hil Medicines, (20110101), pages 1046 - 1052, ISBN 978-0-07-162442-8, XP093192400 |
| OPPOSITION | - Ekaterina Gladysheva et al., "Influencing the decline of lung function in COPD: use of pharmacotherapy", International Journal of COPD, (2010), vol. 5, XP055737093 |
| OPPOSITION | - Emea, "ICH Topic E 9 Statistical Principles for Clinical Trials Step 5 NOTE FOR GUIDANCE ON STATISTICAL PRINCIPLES FOR CLINICAL TRIALS", EMEA CPMP/ICH/363/96, (19980901), pages 1 - 37, EMEA CPMP/ICH/363/96, XP093192237 |
| OPPOSITION | - E.S. Gladysheva et al., "Influencing the decline of lung function in COPD: use of pharmacotherapy", International Journal of COPD, (2010), vol. 5, XP055737093 |
| OPPOSITION | - Fda, "BREO ELLIPTA (fluticasone furoate and vilanterol inhalation powder)", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20131001), pages 1 - 41, HIGHLIGHTS OF PRESCRIBING INFORMATION, XP093192239 |
| OPPOSITION | - Fda, "BREO ELLIPTA (fluticasone furoate and vilanterol inhalation powder)", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20190101), pages 1 - 59, HIGHLIGHTS OF PRESCRIBING INFORMATION, XP093192241 |
| OPPOSITION | - Global Initiative For Chronic Obstructive Lung Disease, "Global Stategy for the Diagnosis, Management and Prevention of Chronic Obstructove Pulmonary Disease", GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE, Global Initiative for Chronic Obstructive Lung disease, (20140101), GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE, XP093192225 |
| OPPOSITION | - Global Initiative For Chronic Obstructive Lung Disease, "GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE", Global Initiative for Chronic Obstructive Lung Disease, (20130101), Global Initiative for Chronic Obstructive Lung Disease, XP093192236 |
| OPPOSITION | - Global Initiative For Chronic Obstructive Lung Disease, "GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE", GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE, Global Initiative for Chronic Obstructive Lung Disease, (20180101), GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE, XP093192226 |
| OPPOSITION | - Hannah R Whittaker et al., "Inhaled corticosteroids, blood eosinophils, and FEV1 decline in patients with COPD in a large UK primary health care setting", International Journal of Chronic Obstructive Pulmonary Disease, (2019), vol. 14, XP093192245 |
| OPPOSITION | - Peter M.A Calverley et al., "Inhaled Corticosteroids Are Beneficial in Chronic Obstructive Pulmonary Disease", AM J Respir Crit Care Med, (2000), vol. 161, XP055737179 |
| OPPOSITION | - Peter M.A. Calverley null, "Inhaled Corticosteroids Are Beneficial in Chronic Obstructive Pulmonary Disease", Am J espir Crit Care Med , (2000), vol. 161, XP055737179 |
| OPPOSITION | - Whittaker Hannah R., Hana Müllerova, Deborah Jarvis, Neil C Barnes, Paul W Jones, Chris H Compton, Steven J Kiddle, Jennifer K Quint , "Online supplement to Inhaled corticosteroids, blood eosinophils, and FEV1 decline in patients with COPD in a large UK primary health care setting", The International journal of chronic obstructive pulmonary disease, (20190401), vol. 14, pages 1 - 18, XP093192245 |
| OPPOSITION | - Jean-Yves Lacoste et al., "Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease", J Allergy Clin Immunol, (1993), vol. 92, doi:10.1016/0091-6749(93)90078-T, XP005930284 |
| OPPOSITION | - LACOSTE J-Y, ET AL., "EOSINOPHILIC AND NEUTROPHILIC INFLAMMATION IN ASTHAM, CHRONIC BRONCHITIS, AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE", Journal of Allergy and Clinical Immunology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (19931001), vol. 92, no. 04, doi:10.1016/0091-6749(93)90078-T, ISSN 0091-6749, pages 537 - 548, XP009070364 |
| OPPOSITION | - Jos Luis Izquierdo Alonso; Jos Miguel Rodrguez Glez-Moro;, "The Excessive Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease", ARCHIVOS DE BRONCONEUMOLOGIA, EDICIONES DOYMA S.A., BARCELONA, ES, ES , (20120108), vol. 48, no. 6, doi:10.1016/j.arbr.2012.03.005, ISSN 1579-2129, pages 207 - 212, XP028485820 |
| OPPOSITION | - Mok, K.H. Pettersson, J. Orrenius, S. Svanborg, C., "HAMLET, protein folding, and tumor cell death", Biochemical and Biophysical Research Communications, Elsevier, Amsterdam NL, Amsterdam NL , (20070123), vol. 354, no. 1, doi:10.1016/j.bbrc.2006.12.167, ISSN 0006-291X, pages 1 - 7, XP005736132 |
| OPPOSITION | - Fernando J Martinez et al., "Fluticasone furoate/vilanterol (100/25; 200/25 mg) improves lung function in COPD: A randomised trial", Respiratory Medicine, (20130116), vol. 107, doi:10.1016/j.rmed.2012.12.016, XP029004010 |
| OPPOSITION | - Fernando J Martinez et al., "Fluticasone furoate/vilanterol (100/25; 200/25 mg) improves lung function in COPD: A randomised trial", Respiratory Medicine, (2013), vol. 107, doi:10.1016/j.rmed.2012.12.016, XP029004010 |
| OPPOSITION | - F.J. Martinez et al., "Fluticasone furoate/vilanterol (100/25; 200/25 mg) improves lung function in COPD: A randomised trial", Respiratory Medicine, (2013), vol. 107, doi:10.1016/j.rmed.2012.12.016, XP029004010 |
| OPPOSITION | - Martinez Fernando J.; Boscia Joseph; Feldman Gregory; Scott-Wilson Catherine; Kilbride Sally; Fabbri Leonardo; Crim Courtney; Calverley Peter M.A., "Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: A randomised tr", Respiratory Medicine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20130116), vol. 107, no. 4, doi:10.1016/j.rmed.2012.12.016, ISSN 0954-6111, pages 550 - 559, XP029004010 |
| OPPOSITION | - Mark T Dransfield et al., "Once-daily inhaled ? uticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials", Lancet Respir Med, (2013), vol. 1, doi:10.1016/S2213-2600(13)70040-7, XP055736138 |
| OPPOSITION | - M.T. Dransfield, Et Al, "Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials", Lancet Respir Med, (20130501), vol. 1, doi:10.1016/S2213-2600(13)70040-7, pages 210 - 223, XP055736138 |
| OPPOSITION | - M.T. Dransfield et al., "Once-daily inhaled-uticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials", Lancet Respir Med, (2013), vol. 1, doi:10.1016/S2213-2600(13)70040-7, XP055736138 |
| OPPOSITION | - Pascoe Steven; Locantore Nicholas; Dransfield Mark T; Barnes Neil C; Pavord Ian D, "Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.", The Lancet. Respiratory medicine, The Lancet Publishing Group, GB, GB , (20150601), vol. 3, no. 6, doi:10.1016/S2213-2600(15)00106-X, ISSN 2213-2619, pages 435 - 442, XP008177095 |
| OPPOSITION | - S. Pascoe et al., "Blood eosinophil counts, exacerbations, and response to the addition of inhaled - uticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials", Lancet Respiratory Medicine , (2015), vol. 3, doi:10.1016/S2213-2600(15)00106-X, XP008177095 |
| OPPOSITION | - Steven Pascoe et al., "Blood eosinophil counts, exacerbations, and response to the addition of inhaled futicasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials", Lancet Respiratory Medicine, (2015), vol. 3, doi:10.1016/S2213-2600(15)00106-X, XP008177095 |
| OPPOSITION | - Scott Karen, Wardlaw Andrew, "Eosinophilic Airway Disorders", SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, THIEME MEDICAL PUBLISHERS, NEW YORK, NY, US, US , (20060401), vol. 27, no. 2, doi:10.1055/s-2006-939515, ISSN 1069-3424, pages 128 - 133, XP093192233 |
| OPPOSITION | - P S Burge et al., "Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial", British Medical Journal , (20000513), vol. 320, doi:10.1136/bmj.320.7245.1297, XP055522775 |
| OPPOSITION | - P S Burge et al., "Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial", British Medical Journal, (2000), vol. 320, doi:10.1136/bmj.320.7245.1297, XP055522775 |
| OPPOSITION | - P.S. Burge et al., "Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial", British Medical Journal, (2000), vol. 320, doi:10.1136/bmj.320.7245.1297, XP055522775 |
| OPPOSITION | - G C Donaldson et al., "Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease", Thorax, (2002), vol. 57, doi:10.1136/thorax.57.10.847, XP055737075 |
| OPPOSITION | - G.C. Donaldson et al., "Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease", Thorax, (2002), vol. 57, doi:10.1136/thorax.57.10.847, XP055737075 |
| OPPOSITION | - G C Donaldson et al., "Relationship between exacerbation frequency and lung funstion decline in chronic obstructive pulmonary disease", Thorax, (2002), vol. 57, doi:10.1136/thorax.57.10.847, XP055737075 |
| OPPOSITION | - C E Brightling et al., "Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease", Thorax, (20050301), vol. 60, doi:10.1136/thx.2004.032516, XP055736134 |
| OPPOSITION | - C E Brightling et al., "Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease", Thorax, (2005), vol. 60, doi:10.1136/thx.2004.032516, XP055736134 |
| OPPOSITION | - C.E. Brightling et al., "Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease", Thorax, (2005), vol. 60, doi:10.1136/thx.2004.032516, XP055736134 |
| OPPOSITION | - E.F.M. Wouters et al., "Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial", Thorax, (2005), vol. 60, doi:10.1136/thx.2004.034280, XP093192221 |
| OPPOSITION | - Wouters E F, "Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial", Thorax, BMJ Publishing Group, GB, GB , (20050601), vol. 60, no. 6, doi:10.1136/thx.2004.034280, ISSN 0040-6376, pages 480 - 487, XP093192221 |
| OPPOSITION | - P. M. Tweedale et al., "Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects", Thorax, (1987), vol. 42, doi:10.1136/thx.42.7.487, XP055736129 |
| OPPOSITION | - P M Tweeddale et al., "Short term variability in FEV1, and bronchodilator responsiveness in patients with obstructive ventilatory defects", Thorax, (19870701), vol. 42, doi:10.1136/thx.42.7.487, XP055736129 |
| OPPOSITION | - P.M. TWEEDDALE et al., "Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects", Thorax , (1987), vol. 42, doi:10.1136/thx.42.7.487, XP055736129 |
| OPPOSITION | - R J Meijer et al., "Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma", Thorax, (1999), vol. 54, doi:10.1136/thx.54.10.894, XP055737122 |
| OPPOSITION | - R.J. Meijer et al., "Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma", Thorax, (1999), vol. 54, doi:10.1136/thx.54.10.894, XP055737122 |
| OPPOSITION | - B.R. Celli et al., "Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study", Am J Respir Crit Care Med, (2008), vol. 178, doi:10.1164/rccm.200712-1869OC, XP093192230 |
| OPPOSITION | - Celli Bartolomé R., Thomas Nicola E., Anderson Julie A., Ferguson Gary T., Jenkins Christine R., Jones Paul W., Vestbo Jørgen, Knobil Katharine, Yates Julie C., Calverley Peter M. A., "Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease : Results from the TORCH Study", American Thoracic Society 2020 International Conference; May 15-20, 2020, American Thoracic Society, (20080815), vol. 178, no. 4, doi:10.1164/rccm.200712-1869OC, ISSN 1073-449X, pages 332 - 338, XP093192230 |
| OPPOSITION | - Bafadhel Mona, Mckenna Susan, Terry Sarah, Mistry Vijay, Reid Carlene, Haldar Pranabashis, Mccormick Margaret, Haldar Koirobi, Kebadze Tatiana, Duvoix Annelyse, Lindblad Kerstin, Patel Hemu, Rugman Paul, Dodson Paul, Jenkins Martin, Saunders Michael, Newbold Paul, Green Ruth H., Venge Per, Lomas David A., Barer Michael R., Johnston Sebastian L., Pavord Ian D., Brightling Christopher E., "Acute Exacerbations of Chronic Obstructive Pulmonary Disease : Identification of Biologic Clusters and Their Biomarkers", American Thoracic Society 2020 International Conference; May 15-20, 2020, American Thoracic Society, (20110915), vol. 184, no. 6, doi:10.1164/rccm.201104-0597OC, ISSN 1073-449X, pages 662 - 671, XP093192214 |
| OPPOSITION | - M Bafadhel et al., "Acute Exacerbations of Chronic Obstructive Pulmonary Disease Identification of Biologic Clusters and Their Biomarkers", Am J Respir Crit Care Med, (2011), vol. 184, doi:10.1164/rccm.201104-0597OC, XP093192214 |
| OPPOSITION | - Mona Bafadhel et al., "Acute Exacerbations of Chronic Obstructive Pulmonary Disease", AM J Respir Crit Care Med, (2011), vol. 184, doi:10.1164/rccm.201104-0597OC, XP055205020 |
| OPPOSITION | - Mona Bafadhel, Susan Mckenna, Sarah Terry, Vijay Mistry, Carlene Reid, Pranabashis Haldar, Margaret Mccormick, Koirobi Haldar, Tatiana Kebadze, Annelyse Duvoix, Kerstin Lindblad, Hemu Patel, Paul Rugman, Paul Dodson, Martin Jenkins, Michael Saunders, Paul Newbold, Ruth H. Green, Per Venge, David A. Lomas, Michael R. Barer, Sebastian L. Johnston, Ian D. Pavord, Christopher E. Brightling, "Acute Exacerbations of Chronic Obstructive Pulmonary Disease", American Journal of Respiratory and Critical Care Medicine, (20110915), vol. 184, no. 6, doi:10.1164/rccm.201104-0597OC, ISSN 1073449X, pages 662 - 671, XP055205020 |
| OPPOSITION | - M. Bafadhel et al., "Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease", American Journal of Respiratory and Critical Care Medicine, (2012), vol. 186, doi:10.1164/rccm.201108-1553OC, XP055204840 |
| OPPOSITION | - Mona Bafadhel, Susan Mckenna, Sarah Terry, Vijay Mistry, Mitesh Pancholi, Per Venge, David A. Lomas, Michael R. Barer, Sebastian L. Johnston, Ian D. Pavord, Christopher E. Brightling, "Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease", American Journal of Respiratory and Critical Care Medicine, (20120701), vol. 186, no. 1, doi:10.1164/rccm.201108-1553OC, ISSN 1073449X, pages 48 - 55, XP055204840 |
| OPPOSITION | - Vestbo Jørgen, Suzanne S. Hurd , Alvar G. Agustí, Paul W. Jones , Claus Vogelmeier , Antonio Anzueto , Peter J. Barnes , Leonardo M. Fabbri , Fernando J. Martinez , Masaharu Nishimura , Robert A. Stockley , Don D. Sin , And Roberto Rodriguez-Roisin, "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease", (20130215), vol. 187, no. 4, doi:10.1164/rccm.201204-0596PP, pages 347 - 365, XP055736897 |
| OPPOSITION | - Vestbo Jørgen, Suzanne S Hurd; Alvar G Agustí, Paul W. Jones , Claus Vogelmeier , Antonio Anzueto , Peter J. Barnes , Leonardo M. Fabbri , Fernando J. Martinez , Masaharu Nishimura , Robert A. Stockley , Don D. Sin , And Roberto Rodriguez-Roisin, "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease", AM J RESPIR CRIT CARE MED, (20130215), vol. 187, no. 4, doi:10.1164/rccm.201204-0596PP, pages 347 - 365, XP055736897 |
| OPPOSITION | - Han et al., "Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy", Am J RRespir Crit Care Med, (2014), vol. 189, doi:10.1164/rccm.201402-0207OC, XP093192223 |
| OPPOSITION | - Han Meilan K., Tayob Nabihah, Murray Susan, Dransfield Mark T., Washko George, Scanlon Paul D., Criner Gerard J., Casaburi Richard, Connett John, Lazarus Stephen C., Albert Richard, Woodruff Prescott, Martinez Fernando J., "Predictors of Chronic Obstructive Pulmonary Disease Exacerbation Reduction in Response to Daily Azithromycin Therapy", American Thoracic Society 2020 International Conference; May 15-20, 2020, American Thoracic Society, (20140615), vol. 189, no. 12, doi:10.1164/rccm.201402-0207OC, ISSN 1073-449X, pages 1503 - 1508, XP093192223 |
| OPPOSITION | - Roopa Trivedi et al., "Umeclidinium in patients with COPD: a randomised, placebo-controlled study", European Respiratory Journal, (2014), vol. 43, doi:10.1183/09031936.00033213, XP055736143 |
| OPPOSITION | - Roopa Trivedi et al., "Umeclidinium in patients with COPD: a randomised, placebo-controlled study", Eur Respir J, (2014), vol. 43, doi:10.1183/09031936.00033213, XP055736143 |
| OPPOSITION | - R. Trivedi et al., "Umeclidinium in patients with COPD: a randomised, placebo-controlled study", Eur Respir J, (2014), vol. 43, doi:10.1183/09031936.00033213, XP055736143 |
| OPPOSITION | - P.W. Jone et al., "Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations", Eur Respir J, (2003), vol. 21, doi:10.1183/09031936.03.00013303, XP055737114 |
| OPPOSITION | - P.W. Jones et al., "Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations", Eur Respir J, (2003), vol. 21, doi:10.1183/09031936.03.00013303, XP055737114 |
| OPPOSITION | - N. Barnes et al., "Blood eosinophils as a marker of response to inhaled corticosteroids in COPD", European Respiratory Journal , (2016), vol. 47, doi:10.1183/13993003.01370-2015, XP055522832 |
| OPPOSITION | - Neil C. Barnes et al., "Blood eosinophils as a marker of response to inhaled corticosteroids in COPD", European Respiratory Journal, (2016), vol. 47, doi:10.1183/13993003.01370-2015, XP055522832 |
| OPPOSITION | - Neil C. Barnes, Raj Sharma, Sally Lettis, Peter M.A. Calverley, "Blood eosinophils as a marker of response to inhaled corticosteroids in COPD", EUROPEAN RESPIRATORY JOURNAL, European Respiratory Society, GB, GB , (20160501), vol. 47, no. 5, doi:10.1183/13993003.01370-2015, ISSN 0903-1936, pages 1374 - 1382, XP055522832 |
| OPPOSITION | - Mathioudakis Alexander, Foden Philip, Vestbo Jorgen, O'hollaren Mark T, Li Hui-An1, "Late Breaking Abstract -Blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids", European Respiratory Journal, (20180101), vol. 52, doi:10.1183/13993003.congress-2018.0A2125, page OA2125, XP093192219 |
| OPPOSITION | - Alexander Mathioudakis et al., "Blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids", European Respiratory Journal, (2018), vol. 52, doi:10.1183/13993003.congress-2018.OA2125, XP055736132 |
| OPPOSITION | - J.A. Falk et al., "Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease", Proc Am Thorac Soc, (2008), vol. 5, doi:10.1513/pats.200707-096ET, XP055736976 |
| OPPOSITION | - Jeremy A. Falk et al., "Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease", Proc Am Thorac Soc, (2008), vol. 5, doi:10.1513/pats.200707-096ET, XP055736976 |
| OPPOSITION | - Whittaker Hannah R, Müllerova Hana, Jarvis Deborah, Barnes Neil C, Jones Paul W, Compton Chris H, Kiddle Steven J, Quint Jennifer K, "Inhaled corticosteroids, blood eosinophils, and FEV1 decline in patients with COPD in a large UK primary health care setting", The International journal of chronic obstructive pulmonary disease, Albany, Auckland : DOVE Medical Press, (20190501), vol. 14, doi:10.2147/COPD.S200919, ISSN 1178-2005, pages 1063 - 1073, XP093192229 |
| OPPOSITION | - Whittaker Hannah R, Müllerova Hana, Jarvis Deborah, Barnes Neil C, Jones Paul W, Compton Chris H, Kiddle Steven J, Quint Jennifer K, "Inhaled corticosteroids, blood eosinophils, and FEV1 decline in patients with COPD in a large UK primary health care setting", The International journal of chronic obstructive pulmonary disease, Albany, Auckland : DOVE Medical Press, (20190501), Volume 14, doi:10.2147/COPD.S200919, ISSN 1178-2005, pages 1063 - 1073, XP093192229 |
| OPPOSITION | - Woods J. Andrew, Wheeler James, Finch Christopher, Pinner Nathan, "Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease", The International journal of chronic obstructive pulmonary disease, Albany, Auckland : DOVE Medical Press, (20140501), vol. 9, doi:10.2147/COPD.S51012, ISSN 1178-2005, pages 421 - 430, XP093192215 |
| SEARCH | - PASCOE STEVEN ET AL, "Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.", THE LANCET. RESPIRATORY MEDICINE JUN 2015, (20150413), vol. 3, no. 6, ISSN 2213-2619, pages 435 - 442, XP008177095 [PA] 1-11 * the whole document * |
| SEARCH | - MONA BAFADHEL ET AL, "Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, (20120701), vol. 186, no. 1, doi:10.1164/rccm.201108-1553OC, ISSN 1073-449X, pages 48 - 55, XP055204840 [DA] 1-11 * whole document, particularly abstract; p. 48, chapter "What this study adds to the field"; discussion * |
| SEARCH | [ ] - NEIL C. BARNES ET AL, "Blood eosinophils as a marker of response to inhaled corticosteroids in COPD", EUROPEAN RESPIRATORY JOURNAL, GB, (20160225), vol. 47, no. 5, doi:10.1183/13993003.01370-2015, ISSN 0903-1936, pages 1374 - 1382, XP055522832 [ ] * the whole document * |
